MicroVue™ FGF-23 ELISA (C-Term)
The MicroVue Human FGF-23 (C-Term) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.
Product Specifications
Citations | 35 |
---|---|
Specimen |
Plasma or Cell Culture Supernatent, 200 µL |
LLOQ | 1.5 RU/mL |
ULOQ | N/A |
Assay Time | 3.5 hours |
Cross Reactivity |
None |
Ordering Information
Catalog Number | 60-6100 |
---|---|
Catalog Number (CE) | |
Size | 96 wells/test |
Price (USD) | $725.00 |
Price (EURO) | 640,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description |
The MicroVue Human FGF-23 (C-Term) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media. |
---|---|
Size | 96 wells/test |
Form |
96 well plate with 12 eight-well strips in a resealable foil pouch |
Specimen | Plasma or Cell Culture Supernatent, 200 µL |
Limit of Detection (LOD) | 1.5 RU/mL |
Lower Limit of Quantitation (LLOQ) | 1.5 RU/mL |
Upper Limit of Quantitation (ULOQ) | N/A |
Intra Assay | 1.4 - 2.4% |
Inter Assay | 2.4 - 4.7% |
Standards | 6 |
Controls | 2 |
Sample Values |
N/A |
Assay Time | 3.5 hours |
Cross Reactivity |
None |
Storage |
Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components |
Background |
Fibroblast growth factor 23 (FGF-23), which is produced by bone cells, is a novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 (aa 1-24) is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion (aa 180-251) shares only limited amino acid homology with other members of the FGF family of proteins. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
2010 | ELISA |
Human |
Plasma |
||
2010 | ELISA |
Human |
Serum |
||
2018 | ELISA |
Human |
Plasma |
Diabetes |
|
Plasma Fibroblast Growth Factor 23 Is Elevated in Pediatric Primary Hypertension. |
2019 | ELISA |
Human |
Plasma |
Hypertension (Children) |
2019 | ELISA |
Human |
Plasma |
||
2020 | ELISA |
Human |
Plasma |
Chronic Kidney Disease |
|
2005 | ELISA |
Human |
Serum |
||
2009 | ELISA |
Human |
Plasma |
||
2009 | ELISA |
Human |
HEK293 cells |
||
2009 | ELISA |
Human |
Plasma |
||
2010 | ELISA |
Human |
Plasma |
||
2010 | ELISA |
Human |
Plasma |
||
2011 | ELISA |
Human |
Serum |
||
Early skeletal and biochemical alterations in pediatric chronic kidney disease |
2012 | ELISA |
Human |
Plasma |
|
2012 | ELISA |
Human |
Serum |
||
2012 | ELISA |
Human |
Serum |
Chronic Kidney Disease |
|
Intact fibroblast growth factor 23 and fragments in plasma from Gambian children |
2013 | ELISA |
Human |
Plasma |
|
Biological variability of plasma intact and C-terminal FGF23 measurements |
2012 | ELISA |
Human |
Plasma |
|
2013 | ELISA |
Human |
Plasma |
||
2013 | ELISA |
Human |
Plasma |
||
2013 | ELISA |
Human |
Serum |
||
Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children |
2013 | ELISA |
Human |
Plasma |
|
The use of fibroblast growth factor 23 testing in patients with kidney disease. |
2014 | ELISA |
Human |
Plasma |
|
2018 | ELISA |
Human |
Plasma |
Acute Coronary Syndrome |
|
2014 | ELISA |
Human |
Plasma |
||
Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients |
2015 | ELISA |
Human |
Plasma |
|
2015 | ELISA |
Human |
Plasma |
MHD |
|
2016 | ELISA |
Human |
Plasma |
Acute Coronary Syndrome |
|
2016 | ELISA |
Human |
Plasma |
||
2016 | ELISA |
Human |
Plasma |
||
2016 | ELISA |
Human |
Plasma |
||
Fibroblast Growth Factor 23-Induced Hypophosphatemia in Acute Leukemia. |
2018 | ELISA |
Human |
Plasma |
|
2018 | ELISA |
Human |
Serum |
||
The Heart and Kidney: Abnormal Phosphate Homeostasis Is Associated With Atherosclerosis. |
2018 | ELISA |
Human |
Plasma |
|
Tumor-induced osteomalacia: experience from three tertiary care centres In India |
2019 | ELISA |
Human |
Serum |
Hypoparathyroidism |